April 10, 2014

Adamas Pharma rises after IPO raises $48 million

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

In morning trading, the stock added $1, or 6.3 percent, to $17.

Adamas Pharmaceuticals Inc. is developing drugs that treat central nervous system disorders such as Parkinson's and Alzheimer's disease. It worked with Forest Laboratories Inc. on Namenda XR, an extended-release version of a Forest drug that treats Alzheimer's. The two companies have been studying a that combines Namenda XR with donepezil, or Aricept. Forest filed for approval of that pill in March.

Shares of the Emeryville, Calif., company are trading under the symbol "ADMS" on the Nasdaq Global Market.

© 2014 The Associated Press. All rights reserved.

Citation: Adamas Pharma rises after IPO raises $48 million (2014, April 10) retrieved 26 April 2024 from https://medicalxpress.com/news/2014-04-adamas-pharma-ipo-million.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

KaloBios Pharma edges higher following IPO
 shares

Feedback to editors
Gene linked to epilepsy and autism decoded in new study

36 minutes ago
Blood test finds knee osteoarthritis up to eight years before it appears on X-rays

39 minutes ago
Researchers find pregnancy cytokine levels impact fetal brain development and offspring behavior

42 minutes ago
Study finds biomarkers for psychiatric symptoms in patients with rare genetic condition 22q

1 hour ago
Clinical trial evaluates azithromycin for preventing chronic lung disease in premature babies

2 hours ago
Scientists report that new gene therapy slows down amyotrophic lateral sclerosis disease progression

2 hours ago
Using stem cell-derived heart muscle cells to advance heart regenerative therapy

2 hours ago
Analysis identifies 50 new genomic regions associated with kidney cancer risk

3 hours ago
Illusion demystifies the way vision works: Experiments imply brightness perception occurs deeper in brain than thought

3 hours ago
How buildings influence the microbiome and human health

3 hours ago
Load comments (0)